<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082433</url>
  </required_header>
  <id_info>
    <org_study_id>CA163-048</org_study_id>
    <nct_id>NCT00082433</nct_id>
  </id_info>
  <brief_title>Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer</brief_title>
  <official_title>A Phase III Study of Novel Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Pharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R-Pharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn if BMS-247550 added to the approved
      therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine
      alone in women with metastatic breast cancer. Patients should have previously received an
      anthracycline and a taxane. The safety of this treatment will also be studied.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>from date of randomization until death</time_frame>
    <description>Overall survival was defined as the time in months from randomization until the date of death. For those patients who had not died, survival duration was censored at the last date the patient was known to be alive. Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>every 6 weeks (± 3 days) from randomization while on treatment until documented progression</time_frame>
    <description>PFS was defined for each patient as the time in months from randomization to the date of progression. Patients who died without a reported prior progression were considered to have progressed on their date of death. Patients who did not progress or die were censored on the date of their last tumor assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>every 6 weeks (± 3 days) from randomization while on treatment until documented progression</time_frame>
    <description>RR=number of patients in that group whose best response is &quot;partial&quot;(30% decrease in the sum of the longest diameter of target lesions) or &quot;complete&quot; (disappearance of all target lesions), according to the 4-item Response Evaluation Criteria in Solid Tumors (RECIST), divided by the total number of response-evaluable participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>every 6 weeks (± 3 days) from randomization while on treatment until documented progression</time_frame>
    <description>Measured from the time RECIST criteria (described in previous outcome measure) were first met for &quot;complete&quot; or &quot;partial&quot; response until first date of documented disease progression or death. Patients who neither relapsed nor died were censored on the date of last tumor assessment. Median w/ 95% CI estimated using Kaplan Meier Product Limit Method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>every 6 weeks (± 3 days) from randomization while on treatment until documented progression</time_frame>
    <description>Time to response was defined as the time from the first dose of study therapy until measurement criteria were first met for &quot;partial&quot; or &quot;complete&quot; (whichever status was recorded first) per RECIST criteria (a 4-item scale described in the previous outcome measure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Safety Summary</measure>
    <time_frame>safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible.</time_frame>
    <description>Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)</measure>
    <time_frame>Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment</time_frame>
    <description>Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1221</enrollment>
  <condition>Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixabepilone + Capecitabine</intervention_name>
    <description>Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle</description>
    <arm_group_label>A</arm_group_label>
    <other_name>IXEMPRA®</other_name>
    <other_name>Epothilone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patients must have received prior treatment which included both an anthracycline
             (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).

          -  Patients must have received no more than two prior chemotherapy regimens. Patients who
             have not received treatment for metastatic disease must have relapsed within one year.

          -  Patients may not have any history of brain and/or leptomeningeal metastases.

          -  Patients may not have Grade 2 or worse neuropathy at the time of study entry.

          -  Patients may not have had prior treatment with any epothilones and/or capecitabine
             (i.e. Xeloda)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Avelianeda</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bahia Blanca</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ciudad Autonoma De Buenos Aires</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Escobar</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Resistencia</city>
        <state>Chaco</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barrio Alto Verde</city>
        <state>Cordoba</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Miguel De Tucuman</city>
        <state>Tucuman</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toowoomba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Voecklabruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Centro-Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bela Vista</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Higienopolis</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <state>Sp</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dilian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Xi'An</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Prague 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kobenhavn O</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 13</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Gregoire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rehling</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saarbrucken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wilton</city>
        <state>Cork</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin 8</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sora</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gyeonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Panorama</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Terassa</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Elche (Alicante)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hospitalet De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jaen</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Thun</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Belfast</city>
        <state>Armagh</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <state>Central</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shrewsbury</city>
        <state>Shropshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2004</study_first_submitted>
  <study_first_submitted_qc>May 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2004</study_first_posted>
  <results_first_submitted>May 1, 2009</results_first_submitted>
  <results_first_submitted_qc>July 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2009</results_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epothilones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>PLEASE NOTE: Completed=number of participants completing ≥18 cycles of treatment; not completed=number of subjects coming off study treatment prior to completing at least 18 cycles, with specified reasons for coming off study treatment. Participants continued to be followed for overall survival.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ixabepilone + Capecitabine</title>
          <description>Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
        </group>
        <group group_id="P2">
          <title>Capecitabine</title>
          <description>Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="609"/>
                <participants group_id="P2" count="612"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15">Participants who received 18 or more cycles of treatment.</participants>
                <participants group_id="P2" count="15">Participants who received 18 or more cycles of treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="594"/>
                <participants group_id="P2" count="597"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression/Relapse</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="388"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Drug Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Still On Treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New primary cancer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Impending surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ixabepilone + Capecitabine</title>
          <description>Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
        </group>
        <group group_id="B2">
          <title>Capecitabine</title>
          <description>Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="609"/>
            <count group_id="B2" value="612"/>
            <count group_id="B3" value="1221"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="532"/>
                    <measurement group_id="B2" value="531"/>
                    <measurement group_id="B3" value="1063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="384"/>
                    <measurement group_id="B2" value="377"/>
                    <measurement group_id="B3" value="761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.0" lower_limit="23.0" upper_limit="78.0"/>
                    <measurement group_id="B2" value="53.0" lower_limit="24.0" upper_limit="81.0"/>
                    <measurement group_id="B3" value="53.0" lower_limit="23.0" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="609"/>
                    <measurement group_id="B2" value="612"/>
                    <measurement group_id="B3" value="1221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="480"/>
                    <measurement group_id="B2" value="502"/>
                    <measurement group_id="B3" value="982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky performance Status</title>
          <description>Karnofsky Performance Scale Index measures a patient's functional impairment: 100-80=able to carry on normal activity and work, no special care; 70-50=unable to work; able to live at home and care for most personal needs with assistance; 40=unable to care for self; requires institutional or hospital care. Score reported in multiples of 10.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Premenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perimenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="475"/>
                    <measurement group_id="B2" value="481"/>
                    <measurement group_id="B3" value="956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Organ Sites</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ascites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="283"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest Wall Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CNS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cutaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intestine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mediastinum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visceral, Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="273"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B3" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visceral, Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visceral, Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence with at least 1 lesion</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="606"/>
                    <measurement group_id="B2" value="612"/>
                    <measurement group_id="B3" value="1218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>PFS was defined for each patient as the time in months from randomization to the date of progression. Patients who died without a reported prior progression were considered to have progressed on their date of death. Patients who did not progress or die were censored on the date of their last tumor assessment.</description>
        <time_frame>every 6 weeks (± 3 days) from randomization while on treatment until documented progression</time_frame>
        <population>All randomized patients with measurable disease as stratified at the time of randomization; n=480 and n=480 for the 2 treatment groups, respectively. Analysis was conducted once 903 progressions or deaths were observed in 960 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone + Capecitabine</title>
            <description>Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>PFS was defined for each patient as the time in months from randomization to the date of progression. Patients who died without a reported prior progression were considered to have progressed on their date of death. Patients who did not progress or die were censored on the date of their last tumor assessment.</description>
          <population>All randomized patients with measurable disease as stratified at the time of randomization; n=480 and n=480 for the 2 treatment groups, respectively. Analysis was conducted once 903 progressions or deaths were observed in 960 participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" lower_limit="5.59" upper_limit="6.77"/>
                    <measurement group_id="O2" value="4.40" lower_limit="4.14" upper_limit="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was conducted when 903 progressions or deaths (446 in combination:457 in capecitabine) were observed in 960 participants.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0005</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>.69</ci_lower_limit>
            <ci_upper_limit>.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (RR)</title>
        <description>RR=number of patients in that group whose best response is &quot;partial&quot;(30% decrease in the sum of the longest diameter of target lesions) or &quot;complete&quot; (disappearance of all target lesions), according to the 4-item Response Evaluation Criteria in Solid Tumors (RECIST), divided by the total number of response-evaluable participants</description>
        <time_frame>every 6 weeks (± 3 days) from randomization while on treatment until documented progression</time_frame>
        <population>Response-evaluable participants (all treated participants with the correct diagnosis of adenocarcinoma originating in the breast who had measurable disease as determined at baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone + Capecitabine</title>
            <description>Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (RR)</title>
          <description>RR=number of patients in that group whose best response is &quot;partial&quot;(30% decrease in the sum of the longest diameter of target lesions) or &quot;complete&quot; (disappearance of all target lesions), according to the 4-item Response Evaluation Criteria in Solid Tumors (RECIST), divided by the total number of response-evaluable participants</description>
          <population>Response-evaluable participants (all treated participants with the correct diagnosis of adenocarcinoma originating in the breast who had measurable disease as determined at baseline).</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" lower_limit="38.7" upper_limit="47.9"/>
                    <measurement group_id="O2" value="28.8" lower_limit="24.7" upper_limit="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.44</ci_lower_limit>
            <ci_upper_limit>2.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Measured from the time RECIST criteria (described in previous outcome measure) were first met for &quot;complete&quot; or &quot;partial&quot; response until first date of documented disease progression or death. Patients who neither relapsed nor died were censored on the date of last tumor assessment. Median w/ 95% CI estimated using Kaplan Meier Product Limit Method.</description>
        <time_frame>every 6 weeks (± 3 days) from randomization while on treatment until documented progression</time_frame>
        <population>Response-evaluable participants (all treated patients with the correct diagnosis of adenocarcinoma originating in the breast who had measurable disease as determined at baseline)</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone + Capecitabine</title>
            <description>Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Measured from the time RECIST criteria (described in previous outcome measure) were first met for &quot;complete&quot; or &quot;partial&quot; response until first date of documented disease progression or death. Patients who neither relapsed nor died were censored on the date of last tumor assessment. Median w/ 95% CI estimated using Kaplan Meier Product Limit Method.</description>
          <population>Response-evaluable participants (all treated patients with the correct diagnosis of adenocarcinoma originating in the breast who had measurable disease as determined at baseline)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.5" upper_limit="7.0"/>
                    <measurement group_id="O2" value="6.3" lower_limit="5.3" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response</title>
        <description>Time to response was defined as the time from the first dose of study therapy until measurement criteria were first met for &quot;partial&quot; or &quot;complete&quot; (whichever status was recorded first) per RECIST criteria (a 4-item scale described in the previous outcome measure).</description>
        <time_frame>every 6 weeks (± 3 days) from randomization while on treatment until documented progression</time_frame>
        <population>Response-evaluable participants (all treated patients with the correct diagnosis of adenocarcinoma originating in the breast who had measurable disease as determined at baseline)</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone + Capecitabine</title>
            <description>Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Time to response was defined as the time from the first dose of study therapy until measurement criteria were first met for &quot;partial&quot; or &quot;complete&quot; (whichever status was recorded first) per RECIST criteria (a 4-item scale described in the previous outcome measure).</description>
          <population>Response-evaluable participants (all treated patients with the correct diagnosis of adenocarcinoma originating in the breast who had measurable disease as determined at baseline)</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="4.7" upper_limit="47.9"/>
                    <measurement group_id="O2" value="6.6" lower_limit="4.6" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Related Safety Summary</title>
        <description>Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTC) Version 3.0</description>
        <time_frame>safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible.</time_frame>
        <population>All patients who received at least 1 dose of ixabepilone and/or capecitabine. Participants with baseline hepatic impairment (combination arm, n = 50; capecitabine arm, n = 37), defined as Grade ≥2 AST, ALT or Grade ≥1 total bilirubin, were contraindicated due to disproportionate number of toxic deaths observed in study CA163-046.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone + Capecitabine</title>
            <description>Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Related Safety Summary</title>
          <description>Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTC) Version 3.0</description>
          <population>All patients who received at least 1 dose of ixabepilone and/or capecitabine. Participants with baseline hepatic impairment (combination arm, n = 50; capecitabine arm, n = 37), defined as Grade ≥2 AST, ALT or Grade ≥1 total bilirubin, were contraindicated due to disproportionate number of toxic deaths observed in study CA163-046.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="595"/>
                <count group_id="O2" value="603"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths within 30 days of last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related Grade 3-4 adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)</title>
        <description>Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.</description>
        <time_frame>Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment</time_frame>
        <population>Analysis was conducted on all randomized participants on an intent to treat basis. (Note: while table only reports data up to 24 wks, which represents most results, statistical analysis includes ALL assessments through study and follow-up; a few participants were assessed after more than 100 weeks.)</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone + Capecitabine</title>
            <description>Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)</title>
          <description>Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.</description>
          <population>Analysis was conducted on all randomized participants on an intent to treat basis. (Note: while table only reports data up to 24 wks, which represents most results, statistical analysis includes ALL assessments through study and follow-up; a few participants were assessed after more than 100 weeks.)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="609"/>
                <count group_id="O2" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=440; n=429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="13.7" lower_limit="-0.96" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.0" spread="4.7" lower_limit="-0.44" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=379; n=353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="15.4" lower_limit="-1.45" upper_limit="-0.31"/>
                    <measurement group_id="O2" value="0.5" spread="5.0" lower_limit="0.02" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=330; n=283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="17.4" lower_limit="-2.15" upper_limit="-0.79"/>
                    <measurement group_id="O2" value="0.7" spread="5.0" lower_limit="0.06" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=283; n=250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="17.3" lower_limit="-2.06" upper_limit="-0.64"/>
                    <measurement group_id="O2" value="1.1" spread="5.2" lower_limit="0.48" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=255; n=240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="17.0" lower_limit="-2.73" upper_limit="-1.15"/>
                    <measurement group_id="O2" value="1.5" spread="5.0" lower_limit="0.90" upper_limit="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 (n=205; n=202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="15.7" lower_limit="-2.07" upper_limit="-0.50"/>
                    <measurement group_id="O2" value="1.2" spread="5.4" lower_limit="0.41" upper_limit="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21 (n=166; n=185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="16.8" lower_limit="-2.36" upper_limit="-0.37"/>
                    <measurement group_id="O2" value="1.7" spread="5.1" lower_limit="0.97" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=149; n=141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="17.3" lower_limit="-2.46" upper_limit="-0.41"/>
                    <measurement group_id="O2" value="1.1" spread="5.4" lower_limit="0.19" upper_limit="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was a statistically significant difference between groups in change from baseline FBSI score favoring capecitabine. A mean change from baseline of 2.5 was considered a clinically meaningful difference (minimally important difference or MID). On-treatment mean changes in the FBSI did not reach the MID in either group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wei-Lachin</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival was defined as the time in months from randomization until the date of death. For those patients who had not died, survival duration was censored at the last date the patient was known to be alive. Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method.</description>
        <time_frame>from date of randomization until death</time_frame>
        <population>Analysis was conducted on all randomized patients on an intent to treat basis. This study required at least 846 events (deaths) to ensure the 2-sided, α = 0.05 level, log-rank test to have 90% power to show a statistically significant difference in OS between treatment groups when the hazard ratio (HR) is 0.8.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone + Capecitabine</title>
            <description>Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival was defined as the time in months from randomization until the date of death. For those patients who had not died, survival duration was censored at the last date the patient was known to be alive. Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method.</description>
          <population>Analysis was conducted on all randomized patients on an intent to treat basis. This study required at least 846 events (deaths) to ensure the 2-sided, α = 0.05 level, log-rank test to have 90% power to show a statistically significant difference in OS between treatment groups when the hazard ratio (HR) is 0.8.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="609"/>
                <count group_id="O2" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.39" lower_limit="14.95" upper_limit="17.91"/>
                    <measurement group_id="O2" value="15.64" lower_limit="13.86" upper_limit="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This primary analysis was a comparison between the 2 treatment arms using a 2-sided, α=0.05 level log-rank test (to reject the null hypothesis of equality of survival). The analysis was conducted when 880 deaths (430 in combination:450 in capecitabine) were observed from the 1221 randomized participants.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.1162</p_value>
            <p_value_desc>The test was stratified by (taxane resistance [yes/no], measurable disease versus non-measurable disease, prior chemotherapy for metastatic disease [yes/no], and anthracycline resistance [yes/no]).</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The analysis was conducted at the 0.05 level and no adjustments were performed</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>.78</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This prespecified secondary analysis was a Cox model adjusted for age, Karnofsky performance status, number of organ sites, estrogen receptor status, hepatic impairment, time from diagnosis, liver/lung metastases.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0231</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>.75</ci_lower_limit>
            <ci_upper_limit>.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Capecitabine</title>
        </group>
        <group group_id="E2">
          <title>Ixabepilone + Capecitabine</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LYMPH NODE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ECTROPION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>EYELID PTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>VISUAL DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BLINDNESS UNILATERAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ULCERATIVE KERATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PANCREATIC CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>EXTRAVASATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CATHETER THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CATHETER SITE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>INJECTION SITE EXTRAVASATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PERFORMANCE STATUS DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HEPATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PORTAL VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MENINGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LYMPHANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>FUNGAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NAIL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>VAGINAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ABDOMINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ANORECTAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CATHETER RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NORWALK VIRUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DRUG TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PUBIC RAMI FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>TRACHEAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>TRANSFUSION REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>DIAGNOSTIC PROCEDURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BLOOD ALBUMIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BLOOD PHOSPHORUS INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PROTHROMBIN TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PATHOLOGICAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>TUMOUR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BREAST NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MALIGNANT ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>METASTASES TO BONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BREAST CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MALIGNANT PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MALIGNANT NEOPLASM PROGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DYSTONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MONOPLEGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>AUTONOMIC NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DEMYELINATING POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>RENAL ATROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ALVEOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BLISTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SKIN REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SWELLING FACE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>EXFOLIATIVE RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SKIN EXFOLIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SKIN DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DERMATITIS EXFOLIATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>STEVENS-JOHNSON SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CATHETER PLACEMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CENTRAL VENOUS CATHETERISATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LYMPHOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>JUGULAR VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="564" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="590" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="315" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="244" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="266" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="272" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>HYPOREFLEXIA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="258" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="245" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>SKIN HYPERPIGMENTATION</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="412" subjects_at_risk="603"/>
                <counts group_id="E2" subjects_affected="383" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial’s primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

